Consider Switching Some VTE Patients to a Low-Dose Direct Oral Anticoagulant

June 2017

More patients will use LOW-dose direct oral anticoagulants (DOACs) long-term to prevent recurrent venous thromboembolism (VTE).

We're used to giving warfarin or a DOAC (Eliquis, etc) for 3 months for patients who have a VTE due to a short-term risk such as surgery or minor trauma.

And we know to use long-term anticoagulation to prevent a VTE recurrence for most patients at high risk...such as those with active cancer or a clotting disorder.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote